Cartesian Therapeutics (RNAC) Receivables - Other (2020 - 2026)

Cartesian Therapeutics (RNAC) has reported Receivables - Other for 5 consecutive years, with $980000.0 the latest figure, recorded in Q3 2024.

• In Q3 2024, Receivables - Other fell 47.73% year-over-year to $980000.0; the TTM figure through Sep 2024 stood at $980000.0 (down 47.73% YoY), while the FY2023 annual figure was $3.0 million, down 5.72% from the prior year.
• Receivables - Other declined to $980000.0 in Q3 2024 per RNAC's latest filing, from $3.5 million in the prior quarter.
• Across five years, Receivables - Other topped out at $3.5 million in Q2 2024 and bottomed at $100000.0 in Q3 2021.
• Historically, Receivables - Other has averaged $1.6 million across 5 years, with a median of $1.1 million in 2023.
• Annual changes were most pronounced in 2021 — Receivables - Other sank 80.0% — and 2024, when it soared 229.1%.
• Cartesian Therapeutics' Receivables - Other stood at $1.0 million in 2020, then sank by 90.0% to $100000.0 in 2021, then jumped by 3062.0% to $3.2 million in 2022, then slipped by 5.72% to $3.0 million in 2023, then slumped by 67.13% to $980000.0 in 2024.
• Business Quant data shows RNAC's Receivables - Other at $980000.0 in Q3 2024, $3.5 million in Q2 2024, and $2.4 million in Q1 2024.